Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Biomed Pharmacother ; 88: 52-60, 2017 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-28092845

RESUMO

Cinnamon has a history of use for medicinal purposes and its major benefits have been linked to cinnamaldehyde. The present study aimed to investigate the hypoglycemic action of cinnamaldehyde against fatty-sucrosed diet/streptozotocin (FSD/STZ)-rat model of gestational diabetes. Female albino rats were divided into three groups. Group I fed with normal diet (ND) while group II and III were fed with FSD for eight weeks (five weeks pre-gestational and three weeks gestational). Rats of group III were administered with a daily oral dose of 20mg/kg cinnamaldehyde one week before mating onward. At the 7th day of gestation, FSD-fed rats were injected intraperitoneally with STZ (25mg/kg b.wt.) to induce gestational diabetes. Pre-mating treatment of cinnamaldehyde controls hyperphagia and glucose intolerance during the gestational period than in diabetic rats. It also reduced levels of fructosamine, total cholesterols, triglycerides, leptin, tumor necrosis factor-alpha (TNF-α), malondialdehyde (MDA) and nitric oxide (NO), while it significantly increased levels of high-density lipoprotein (HDL)-cholesterol, adiponectin, liver glycogen, reduced glutathione (GSH) and catalase activity at term pregnancy. In addition, cinnamaldehyde administration up-regulated the mRNA expression of peroxisome proliferated activated receptor-gamma (PPARγ) and also ameliorated the number of viable fetuses, implantation loss sites, fetal glucose and insulin levels. In conclusion, cinnamaldehyde has safe hypoglycemic action on gestational diabetes by potentiating insulin secretion and sensitivity through activating the antioxidant defense system, suppressing pro-inflammatory cytokines production, upregulating PPARγ gene expression and alleviating the reproductive performance.


Assuntos
Acroleína/análogos & derivados , Citocinas/metabolismo , Diabetes Gestacional/tratamento farmacológico , Diabetes Gestacional/patologia , Hiperglicemia/tratamento farmacológico , Mediadores da Inflamação/metabolismo , Estresse Oxidativo , PPAR gama/metabolismo , Acroleína/farmacologia , Acroleína/uso terapêutico , Tecido Adiposo/metabolismo , Animais , Antioxidantes/metabolismo , Biomarcadores/metabolismo , Glicemia/metabolismo , Peso Corporal/efeitos dos fármacos , Colesterol/sangue , Diabetes Gestacional/sangue , Diabetes Gestacional/genética , Comportamento Alimentar/efeitos dos fármacos , Feminino , Feto/metabolismo , Frutosamina/sangue , Teste de Tolerância a Glucose , Glicogênio/metabolismo , Hiperglicemia/sangue , Hiperglicemia/genética , Hiperglicemia/patologia , Insulina/sangue , Leptina/sangue , Fígado/metabolismo , Estresse Oxidativo/efeitos dos fármacos , PPAR gama/genética , Gravidez , Resultado da Gravidez , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Ratos , Triglicerídeos/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...